Multimodal FDG-PET and EEG assessment improves diagnosis and prognostication of disorders of consciousness.


Journal

NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070

Informations de publication

Date de publication:
2021
Historique:
received: 10 10 2020
revised: 05 02 2021
accepted: 11 02 2021
pubmed: 3 3 2021
medline: 31 7 2021
entrez: 2 3 2021
Statut: ppublish

Résumé

Functional brain-imaging techniques have revealed that clinical examination of disorders of consciousness (DoC) can underestimate the conscious level of patients. FDG-PET metabolic index of the best preserved hemisphere (MIBH) has been reported as a promising measure of consciousness but has never been externally validated and compared with other brain-imaging diagnostic procedures such as quantitative EEG. FDG-PET, quantitative EEG and cognitive evoked potential using an auditory oddball paradigm were performed in minimally conscious state (MCS) and vegetative state (VS) patient. We compared out-sample diagnostic and prognostic performances of PET-MIBH and EEG-based classification of conscious state to the current behavioral gold-standard, the Coma Recovery Scale - revised (CRS-R). Between January 2016 and October 2019, 52 patients were included: 21 VS and 31 MCS. PET-MIBH had an AUC of 0.821 [0.694-0.930], sensitivity of 79% [62-91] and specificity of 78% [56-93], not significantly different from EEG (p = 0.628). Their combination accurately identified almost all MCS patients with a sensitivity of 94% [79-99%] and specificity of 67% [43-85]. Multimodal assessment also identified VS patients with neural correlate of consciousness (4/7 (57%) vs. 1/14 (7%), p = 0.025) and patients with 6-month recovery of command-following (9/24 (38%) vs. 0/16 (0%), p = 0.006), outperforming each technique taken in isolation. FDG-PET MIBH is an accurate and robust procedure across sites to diagnose MCS. Its combination with EEG-based classification of conscious state not only optimizes diagnostic performances but also allows to detect covert cognition and to predict 6-month command-following recovery demonstrating the added value of multimodal assessment of DoC.

Identifiants

pubmed: 33652375
pii: S2213-1582(21)00045-0
doi: 10.1016/j.nicl.2021.102601
pmc: PMC7921007
pii:
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102601

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Bertrand Hermann (B)

Institut du Cerveau et de la Moelle épinière - ICM, Inserm U1127, CNRS UMR 7225, F-75013 Paris, France; Faculté de Médecine, Université de Paris, Paris, France; Service de Médecine Intensive et Réanimation, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France. Electronic address: bertrand.hermann@aphp.fr.

Johan Stender (J)

Institut du Cerveau et de la Moelle épinière - ICM, Inserm U1127, CNRS UMR 7225, F-75013 Paris, France.

Marie-Odile Habert (MO)

Faculté de Médecine Pitié-Salpêtrière, Sorbonne Universités, UPMC Université Paris 06, Paris, France; Laboratoire d'Imagerie Biomédicale, Sorbonne Université, UPMC Université Paris 06, CNRS, INSERM, F-75013 Paris, France; Service de Médecine Nucléaire, Groupe hospitalier Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.

Aurélie Kas (A)

Faculté de Médecine Pitié-Salpêtrière, Sorbonne Universités, UPMC Université Paris 06, Paris, France; Laboratoire d'Imagerie Biomédicale, Sorbonne Université, UPMC Université Paris 06, CNRS, INSERM, F-75013 Paris, France; Service de Médecine Nucléaire, Groupe hospitalier Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.

Mélanie Denis-Valente (M)

Institut du Cerveau et de la Moelle épinière - ICM, Inserm U1127, CNRS UMR 7225, F-75013 Paris, France; Service de Neurophysiologie, Groupe hospitalier Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.

Federico Raimondo (F)

Institut du Cerveau et de la Moelle épinière - ICM, Inserm U1127, CNRS UMR 7225, F-75013 Paris, France; Coma Science Group, GIGA Consciousness, University of Liège, Belgium; Centre du Cerveau(2), University Hospital of Liège, Belgium.

Pauline Pérez (P)

Institut du Cerveau et de la Moelle épinière - ICM, Inserm U1127, CNRS UMR 7225, F-75013 Paris, France.

Benjamin Rohaut (B)

Institut du Cerveau et de la Moelle épinière - ICM, Inserm U1127, CNRS UMR 7225, F-75013 Paris, France; Faculté de Médecine Pitié-Salpêtrière, Sorbonne Universités, UPMC Université Paris 06, Paris, France.

Jacobo Diego Sitt (JD)

Institut du Cerveau et de la Moelle épinière - ICM, Inserm U1127, CNRS UMR 7225, F-75013 Paris, France.

Lionel Naccache (L)

Institut du Cerveau et de la Moelle épinière - ICM, Inserm U1127, CNRS UMR 7225, F-75013 Paris, France; Faculté de Médecine Pitié-Salpêtrière, Sorbonne Universités, UPMC Université Paris 06, Paris, France; Service de Neurophysiologie, Groupe hospitalier Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH